A Nature Communications study examined whether GLP-1 receptor agonists affect tuberculosis risk in people with type 2 diabetes. The analysis focused on the intersection of commonly prescribed metabolic therapies and infectious disease vulnerability, adding evidence relevant to safety monitoring and real-world prescribing. For biopharma, the finding reinforces the need for pharmacoepidemiology work that captures longer-term, population-level risks that may not surface in pre-approval trials.